Capital One Financial Begins Coverage on Heron Therapeutics (NASDAQ:HRTX)

Analysts at Capital One Financial started coverage on shares of Heron Therapeutics (NASDAQ:HRTX) in a note issued to investors on Tuesday, Marketbeat.com reports. The brokerage set an “overweight” rating and a $6.00 price target on the biotechnology company’s stock. Capital One Financial‘s price objective indicates a potential upside of 126.42% from the company’s previous close.

HRTX has been the topic of several other research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 price objective on shares of Heron Therapeutics in a research note on Thursday, April 11th. StockNews.com raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th.

Heron Therapeutics Stock Down 5.4 %

HRTX stock opened at $2.65 on Tuesday. The business’s fifty day moving average is $2.75 and its 200-day moving average is $1.96. The company has a market cap of $398.37 million, a P/E ratio of -3.08 and a beta of 1.68. Heron Therapeutics has a twelve month low of $0.50 and a twelve month high of $3.22.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Tuesday, March 12th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.08. The company had revenue of $34.23 million during the quarter, compared to analyst estimates of $30.98 million. Research analysts anticipate that Heron Therapeutics will post -0.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Heron Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. grew its holdings in Heron Therapeutics by 100.0% during the third quarter. Adage Capital Partners GP L.L.C. now owns 2,000,000 shares of the biotechnology company’s stock worth $2,060,000 after purchasing an additional 1,000,000 shares during the period. JW Asset Management LLC lifted its position in Heron Therapeutics by 9.1% during the third quarter. JW Asset Management LLC now owns 2,407,418 shares of the biotechnology company’s stock worth $2,480,000 after acquiring an additional 200,000 shares during the last quarter. Congress Park Capital LLC lifted its position in Heron Therapeutics by 205.3% during the fourth quarter. Congress Park Capital LLC now owns 1,798,650 shares of the biotechnology company’s stock worth $3,058,000 after acquiring an additional 1,209,500 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Heron Therapeutics during the third quarter worth approximately $31,000. Finally, Tejara Capital Ltd lifted its position in Heron Therapeutics by 28.6% during the third quarter. Tejara Capital Ltd now owns 2,109,681 shares of the biotechnology company’s stock worth $2,173,000 after acquiring an additional 469,548 shares during the last quarter. Institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.